HealthDay: Empagliflozin Offers Clinical Benefit in Heart Failure

April 14, 2022

For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation to coincide with the annual meeting of the American College of Cardiology, held from April 2 to 4 in Washington, D.C.

Mikhail N. Kosiborod, MD, from Saint Luke's Mid America Heart Institute in Kansas City, Missouri, and colleagues conducted a secondary analysis to examine the impact of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life among patients hospitalized for acute heart failure. 

"Our results are of clinical importance, because very few therapies have been previously shown to improve symptoms and functional status in the early postdischarge period in individuals hospitalized with acute heart failure," the authors write.

Read the full HealthDay article: Empagliflozin Offers Clinical Benefit in Heart Failure

Related Content

Healio: Empagliflozin Benefits Acute HF Regardless of Baseline Impairment: EMPULSE
Study shows patients with acute heart failure assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo.
TCTMD: Quality of Life Gains Within 15 Days in Acute Heart Failure with Empagliflozin: EMPULSE Analysis
A secondary analysis of the EMPULSE trial provides more context to the quality-of-life benefits of the early initiation of empagliflozin in patients hospitalized with acute decompensated heart failure.
Medscape logo
Medscape: Empagliflozin Rapidly Improves Acute Heart Failure Symptoms in Hospitalized Patients
EMPULSE trial shows treatment of patients acutely hospitalized for heart failure with empagliflozin led to a rapid incremental increase in patient well-being, compared with control patients who received placebo.